LFCM
IOVA icon

Long Focus Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Long Focus Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.74M Hold
2,100,000
– – 0.22% 63
2026
Q1 		$7.37M Sell
2,100,000
-6,500,000
-76% -$20.8M 0.19% 73
2025
Q4 		$23.5M Sell
8,600,000
-516,507
-6% -$1.19M 0.62% 42
2025
Q3 		$19.8M Sell
9,116,507
-2,703,493
-23% -$6.38M 0.65% 43
2025
Q2 		$20.3M Buy
11,820,000
+2,569,945
+28% +$6.39M 0.77% 36
2025
Q1 		$30.8M Buy
9,250,055
+4,118,055
+80% +$21.2M 1.03% 22
2024
Q4 		$38M Buy
5,132,000
+600,000
+13% +$5.56M 1.23% 17
2024
Q3 		$42.6M Buy
4,532,000
+400,000
+10% +$3.79M 1.49% 15
2024
Q2 		$33.1M Buy
4,132,000
+2,731,688
+195% +$29.3M 1.27% 17
2024
Q1 		$20.8M Sell
1,400,312
-735,209
-34% -$8.56M 1.06% 20
2023
Q4 		$17.4M Sell
2,135,521
-335,000
-14% -$1.75M 0.58% 19
2023
Q3 		$11.2M Buy
2,470,521
+593,707
+32% +$3.88M 0.4% 31
2023
Q2 		$13.2M Sell
1,876,814
-185,000
-9% -$1.32M 0.6% 22
2023
Q1 		$12.6M Hold
2,061,814
– – 0.71% 26
2022
Q4 		$13.2M Buy
2,061,814
+1,125,814
+120% +$8.79M 0.91% 19
2022
Q3 		$8.97M Sell
936,000
-689,000
-42% -$7.95M 0.87% 21
2022
Q2 		$17.9M Buy
1,625,000
+920,000
+130% +$12.1M 1.88% 11
2022
Q1 		$11.7M Buy
705,000
+180,000
+34% +$2.78M 1.51% 15
2021
Q4 		$10M Buy
+525,000
New +$11.6M 1.33% 13

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Long Focus Capital Management's IOVA Position: Q2 2026 in Review

Long Focus Capital Management held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 2,100,000 shares worth $8.74M. The position accounts for 0.22% of the portfolio, ranked #63.

Long Focus Capital Management first reported a position in IOVA in Q4 2021 and has held it in 19 quarters since. The position peaked at $42.6M in Q3 2024. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Long Focus Capital Management held 2,100,000 shares of Iovance Biotherapeutics worth $8.74M as of Q2 2026.
  • Long Focus Capital Management left its Iovance Biotherapeutics share count unchanged in Q2 2026.
  • Iovance Biotherapeutics made up 0.22% of Long Focus Capital Management's portfolio in Q2 2026, its #63 holding.
  • Long Focus Capital Management first reported a position in Iovance Biotherapeutics in Q4 2021 and has held it in 19 quarters since.
  • Long Focus Capital Management's Iovance Biotherapeutics position peaked at $42.6M in Q3 2024.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Long Focus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.